TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01337375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa 2a [Pegasys]
Description: sc weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: iv weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: sc twice weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: iv twice weekly
Study: NCT04786756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: 1 mg/kg Bupivacaine (0.25%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: 1 mg/kg Bupivacaine (0.25%)
Study: NCT03414047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV
Study: NCT04560478

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pro Seal Sealant
Description: Sealant was reapplied every 3 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MI Varnish
Description: Fluoride varnish was applied every 4-6 weeks
Study: NCT03530462

Intervention type: DRUG
Intervention: rituximab
Description: 375 mg/m2 weekly for 4 weeks

Intervention type: DRUG
Intervention: cyclophosphamide
Description: 750 mg/m2 monthly for 4-6 cycles depending on the response

Intervention type: DRUG
Intervention: Steroids
Description: 500-1000 mg of methylprednisolone daily for 3 days, then tapered doses

Intervention type: DRUG
Intervention: Steroids
Description: 500-1000 mg of methylprednisolone daily for 3 days, then tapered doses

Intervention type: DRUG
Intervention: Intravenous immunoglobulin
Description: intravenous immunoglobulin (IVIG) with or without plasmapheresis

Intervention type: DRUG
Intervention: Intravenous immunoglobulin
Description: intravenous immunoglobulin (IVIG) with or without plasmapheresis
Study: NCT00926380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: denosumab: 60 mg SC every 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: denosumab: 60 mg SC every 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: teriparatide: 20 mcg SC QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: teriparatide: 20 mcg SC QD
Study: NCT01321723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH analog
Description: A recombinant 1-31 amino acid fragment of PTH.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forsteo (Teriparatide)
Description: A recombinant 1-34 amino acid fragment of PTH.
Study: NCT05623813

Intervention type: OTHER
Intervention: Postoperative education
Description: provide patients with the understanding and confidence to safely engage in their daily activities whilst following post-sternotomy precautionary guidelines throughout their recovery

Intervention type: OTHER
Intervention: Postoperative education
Description: provide patients with the understanding and confidence to safely engage in their daily activities whilst following post-sternotomy precautionary guidelines throughout their recovery
Study: NCT00713206

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implant (Osseotite)
Description: Root form titanium dental implant
Study: NCT03516045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AlF-NOTA-neurotensin
Description: One injection of the radioligand 18F-AlF-NOTA-neurotensin
Study: NCT06295042

Intervention type: OTHER
Intervention: BREAST-Q Questionnaire
Description: Patient-reported outcome measure

Intervention type: OTHER
Intervention: BREAST-Q Questionnaire
Description: Patient-reported outcome measure
Study: NCT02062112

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pattern of flavoring of bowel laxative
Description: Unflavored bowel laxative versus entire bowel laxative flavored versus liberal flavoring as decided by patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pattern of flavoring of bowel laxative
Description: Unflavored bowel laxative versus entire bowel laxative flavored versus liberal flavoring as decided by patient
Study: NCT02134366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam
Description: Comparison of AED use in Epilepsia Partialis Continua

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobazam
Description: Comparison of AED use in Epilepsia Partialis Continua

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobazam
Description: Comparison of AED use in Epilepsia Partialis Continua

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: Comparison of AED use in Epilepsia Partialis Continua

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam
Description: Comparison of AED use in Epilepsia Partialis Continua

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam
Description: Comparison of AED use in Epilepsia Partialis Continua

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Comparison of AED use in Epilepsia Partialis Continua

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Comparison of AED use in Epilepsia Partialis Continua

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Comparison of AED use in Epilepsia Partialis Continua
Study: NCT04693910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia-Based Hormone Therapy Information Program
Description: The multimedia hormone therapy information program lasted 6 weeks and covered 6 topics, namely the recognition of hormone therapy and multimedia information programs, mindfulness, exercise, stress relief, positive thinking, and prevention or reduction of fatigue.
Study: NCT04672798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRITEPath
Description: BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: Participants in this group will receive usual care from their mental health care provider.
Study: NCT02550483

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Base diet + high beta-carotene tomato juice
Description: Participants will receive high beta-carotene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Base diet + high lycopene tomato juice
Description: Participants will receive high lycopene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Base diet + placebo beverage
Description: Participants will receive a placebo beverage daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
Study: NCT01963715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN289
Study: NCT03211728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: The intervention group receive pregabalin 150 mg 1 hour before surgery and 12 hours after initial dose.
Study: NCT01232374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 200mg (4 bottles), once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.~Placebo: 4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.~Placebo: 4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
Study: NCT01027897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Doripenem 1 gm administered over 4 hours X 3 doses
Study: NCT04757233

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GlucoType
Description: GlucoType is an mobile Health intervention for facilitating self-management in T2DM built for iPhone and Android smartphones. GlucoType includes a custom-built interface for low-burden capture of diet and blood glucose (BG) levels and relies on a commercial activity tracker, FitBit, for capture of sleep and physical activity. It then applies computational phenotyping techniques to identify patterns of associations between daily activities and changes in BG levels. GlucoType uses an expert system developed by our research team to translate identified phenotypes into automatically-generated personalized behavioral goals for improving glycemic control formulated in natural language.
Study: NCT04343365

Intervention type: OTHER
Intervention: Evolutionary Tumor Board (ETB)
Description: The ETB consists of evolutionary biologists, mathematicians, research scientists, statisticians,data scientists, radiologists, pathologists, oncologists (surgical, radiation, medical, and pediatric), and clinical trial coordinators.The ETB will generate hypotheses, mathematical models, and experiments from the discussion towards further integration of evolutionary ideas towards therapeutic strategies for participants. The ETB will collect data through a chart review regarding adherence and results of ETB recommendation
Study: NCT02634710

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Treatments will have a minimum of a 48-hour interfraction interval. Treatments will be completed over 20 days maximum.
Study: NCT04607980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 654
Description: Participants will receive SC injection of ABP 654.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 654
Description: Participants will receive SC injection of ABP 654.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Participants will receive SC injection of ustekinumab.
Study: NCT03965455

Intervention type: DEVICE
Intervention: Diode laser
Description: In the laser-assisted frenectomy, a diode laser device (GIGA Cheese II®, China) (λ= 810 nm) with a 400 µm diameter, plain-ended optical ﬁber tip was used for the procedure maintaining contact with oral mucosa at 2,5 W, 70 Hz frequency with a short pulse (140 microseconds) duration.

Intervention type: PROCEDURE
Intervention: Conventional
Description: In the conventional frenectomy, the incisions were applied using a scalpel blade no.15 on the upper and lower surface of the haemostat until the frenum was excised.
Study: NCT03027076

Intervention type: PROCEDURE
Intervention: Genitourinary Specimen Collection
Description: Collect urethral swab, urine before prostatic massage (pre-M), urine after prostatic massage (post-M) and Expressed Prostatic Secretion (EPS)

Intervention type: PROCEDURE
Intervention: Genitourinary Specimen Collection
Description: Collect urethral swab, urine before prostatic massage (pre-M), urine after prostatic massage (post-M) and Expressed Prostatic Secretion (EPS)

Intervention type: PROCEDURE
Intervention: Collect midstream urine samples
Description: Collect midstream urine samples

Intervention type: PROCEDURE
Intervention: Collect midstream urine samples
Description: Collect midstream urine samples
Study: NCT03211728

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo group receive placebo 150 mg 1 hour before surgery and 12 hours after initial dose.
Study: NCT01764659

Intervention type: OTHER
Intervention: Contrast-enhanced 4D computed tomography
Description: All enrolled patients each underwent three CT scans: a 4DCT immediately following a contrast-enhanced 3DCT and an individually optimized contrast-enhanced 4DCT.
Study: NCT01815775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical and imaging examinations
Description: Quantitative CSF flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid flow was measured with a velocity-encoding value of 10-20 cm/s. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in neuropsychological assessment (including mini mental state examination test and Bradley's scale) as well as Hakim's triad evaluation
Study: NCT04564924

Intervention type: RADIATION
Intervention: DXA
Description: Bone mineral density was examined in all cases and controls

Intervention type: RADIATION
Intervention: DXA
Description: Bone mineral density was examined in all cases and controls
Study: NCT00570180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 21 day-cycle Induction therapy:bortezomib 1.3 mg/m2 (I.V. Days 1, 4, 8, and 11), then 10-day rest period. DOXIL 30 mg/m2 given after bortezomib (I.V. infusion Day 4 of each cycle). Dexamethasone 40 mg PO on days 1-4,8-11 and 15-18 during the first cycle. Subsequent 3 cycles, dexamethasone 40 mg PO given on days 1-4 and 11-14. Patients who don't progress may undergo elective stem cell mobilization, stem cell collection and cryopreservation. Patients will then receive post-induction therapy 1.5 mg/m2 bortezomib days 1, 8, and 15 I.V. + cyclophosphamide 300 mg/m2 PO weekly + prednisone 100 mg PO on alternate days for 8 monthly 28 day cycles.Maintenance therapy with weekly 40 mg dexamethasone (days 1, 8, 15 and 22) every month until disease progression occurs.
Study: NCT02929134

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients \>50 kg or 100 mg per day for patients \<50 kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily tablet for 6 weeks: matching tablets containing no active ingredients
Study: NCT02687295

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Thylakoids

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study: NCT02550704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability
Description: Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin, occludin and ZO-1.
Study: NCT00524173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir & Emtricitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Study: NCT02840396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: repetitive TMS (rTMS) can lead to temporary increases or decreases (depending on the protocol used) in excitability of the targeted area. This change in excitability has been shown to last beyond the duration of the stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS (or placebo rTMS) refers to a control condition in which no physiological effect on the targeted cortical region occurs.
Study: NCT03864289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent skills training
Description: Parents of children with autism spectrum disorder attend the parental training course once a week, and there was a total of eight courses with each course lasting 3 hours
Study: NCT03818776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (MEDI4736) is an anti-PD-L1 monoclonal antibody immunotherapy for lung cancer. Participants will receive 1500mg durvalumab via intravenous (IV) infusion Q4W for up to a maximum of 12 months (up to 13 doses/cycles) with the last administration on week 48 unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. (N.b. If a participant's weight falls to 30kg (≤30 kg)), then the participant should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W after consultation between Investigator and Study Physician, until the weight improves to above 30 kg \>30 kg, at which point the participant should start receiving the fixed dosing of durvalumab 1500 mg Q4W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (MEDI4736) is an anti-PD-L1 monoclonal antibody immunotherapy for lung cancer. Participants will receive 1500mg durvalumab via intravenous (IV) infusion Q4W for up to a maximum of 12 months (up to 13 doses/cycles) with the last administration on week 48 unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. (N.b. If a participant's weight falls to 30kg (≤30 kg)), then the participant should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W after consultation between Investigator and Study Physician, until the weight improves to above 30 kg \>30 kg, at which point the participant should start receiving the fixed dosing of durvalumab 1500 mg Q4W).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam therapy RT
Description: Proton beam therapy is a type of RT where the proton stops at a specific depth according to its energy which allows for a sufficient tumor dose that may improve local control and survival while sparing normal organs at risk, such as the heart, lung, and spinal cord.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam therapy RT
Description: Proton beam therapy is a type of RT where the proton stops at a specific depth according to its energy which allows for a sufficient tumor dose that may improve local control and survival while sparing normal organs at risk, such as the heart, lung, and spinal cord.
Study: NCT00473824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis C Immune Globulin Intravenous (Human) 5%
Description: Hepatitis C Immune Globulin Intravenous (Human) 5%, \[Civacir\]: 18 infusions total, per schedule, of 300 or 400 mg/kg of body weight given with standard post-transplant therapy inclusive of immunosuppressive agents.
Study: NCT05822206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-TSC
Description: Cognitive Behavioral Therapy for Trauma and Self-Care

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Life Steps and Sexual Decision-Making

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Steps and Sexual Decision-Making
Study: NCT02589834

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quran group
Study: NCT02696434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: daily dosing
Study: NCT03381469

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comprehensive periodontal treatment
Description: The Case group participants will receive non-surgical periodontal therapy that will be completed by the end of week 20-21 of gestation. This will consist of oral hygiene instruction with comprehensive periodontal treatment which will include excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth followed by supragingival and subgingival scaling and root planing (SRP) of sites with PDs \> 4 mm and polishing of all the teeth. Participants will be offered treatment under local anesthetic when necessary. No limits will be imposed on the number of dental visits needed to accomplish periodontal therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single visit supragingival scaling
Description: The control and Placebo group participants will receive oral hygiene instruction and supragingival cleaning of all teeth at their baseline visit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single visit supragingival scaling
Description: The control and Placebo group participants will receive oral hygiene instruction and supragingival cleaning of all teeth at their baseline visit.